In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

BACKGROUND: Uterine serous papillary adenocarcinoma (USPC) is a rare but highly aggressive variant of endometrial cancer. Pertuzumab is a new humanised monoclonal antibody (mAb) targeting the epidermal growth factor type II receptor (HER2/neu). We evaluated pertuzumab activity separately or in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Sahwi, K, Bellone, S, Cocco, E, Cargnelutti, M, Casagrande, F, Bellone, M, Abu-Khalaf, M, Buza, N, Tavassoli, F A, Hui, P, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813756/
https://www.ncbi.nlm.nih.gov/pubmed/19920829
http://dx.doi.org/10.1038/sj.bjc.6605448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813756/
https://www.ncbi.nlm.nih.gov/pubmed/19920829
http://dx.doi.org/10.1038/sj.bjc.6605448

Ejemplares similares